The Ring Study
The Ring Study, a clinical trial now underway by the International Partnership for Microbicides, is designed to determine whether IPM's monthly vaginal ring that delivers the ARV drug dapivirine helps prevent HIV infection in women and is safe for long-term use.
The first efficacy study of a vaginal ring for HIV prevention, The Ring Study is fully enrolled with 1,959 women ages 18-45 across six sites in South Africa and one site in Uganda.
The dapivirine ring licensure program
The Ring Study is part of IPM’s broader Dapivirine Ring Licensure Program.
The full licensure program also includes ASPIRE, a "sister" efficacy and safety study of the dapivirine ring being led by IPM's clinical trial partner, the US NIH-funded Microbicide Trials Network (MTN). ASPIRE is fully enrolled with 2,629 women ages 18-45 across 15 sites in Malawi, South Africa, Uganda, and Zimbabwe.
Together, the two studies involve thousands of women volunteers across Africa. Efficacy results of both trials are expected by early 2016.
Should the studies show the ring to be safe and effective, IPM will seek regulatory approval for the ring's licensure and collaborate with key partners to help ensure the ring is made available at low cost as soon as possible to women in developing countries.
IPM’s ring uses a novel delivery method that slowly releases the ARV dapivirine over time, and is designed to remain in place for at least one month to provide sustained, discreet and easy-to-use protection against HIV.